Trial Profile
An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys and Viread and REP 2165-Mg in Combination With Pegasys and Viread in Patients With HBeAg Negative Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs REP 2139 (Primary) ; REP 2165 (Primary) ; Interferon alpha-2a; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors REPLICor
- 24 Jul 2023 According to Replicor media release, this study is part of an ongoing collaboration with Dr. Harel Dahari's team at Loyola University (Chicago, USA)
- 24 Jul 2023 According to Replicor media release, results from this trial were published in the Hepatology Communications.
- 24 Jul 2023 Results presented in the REPLICor Media Release.